6 completed, 1 active not recruiting, 1 terminated, 1 unknown. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 6, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Netherton Syndrome: new trials by email Literature Review of Netherton Syndrome trials Research Report on Netherton Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 BCX17725, Placebo - Netherton Syndrome | Phase 1 | Active not recruiting | BioCryst Pharmaceuticals | 76 | 2024-09-26 | 2026-11-06 |
| Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome ATR12-351 - Netherton Syndrome | Phase 1 | Completed | Azitra Inc. | 6 | 2024-06-16 | 2026-07-29 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 24 | 2022-11-08 | 2023-05-18 |
| A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 64 | 2022-06-20 | 2023-03-06 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| Gene Therapy for Netherton Syndrome One 20cm2/10cm2 autologous skin sheet graft - Netherton Syndrome | Phase 1 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 5 | 2014-04-01 | 2016-10-19 |
| A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment - Healthy Volunteers, Atopic Dermatitis | Phase 1 | Completed | Novartis Pharmaceuticals | 12 | 2011-05-01 | 2020-12-08 |
| Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome Pimecrolimus 1% Cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 3 | 2005-09-01 | 2019-08-14 |
Dermatitis, Atopic (1) · Eczema (1) · Ichthyosis (1) · Skin Diseases (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Genetic (1)
Abnormalities, Multiple (9) · Congenital Abnormalities (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Ichthyosiform Erythroderma, Congenital (9) · Infant, Newborn, Diseases (9) · Keratosis (9) · Skin Abnormalities (9) · Skin and Connective Tissue Diseases (9) · Ichthyosis (8) · Skin Diseases (8) · Skin Diseases, Genetic (8) · Dermatitis (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1)
WAS protein, human (1) · pimecrolimus (1)
Daiichi Sankyo (3) · Azitra Inc. (1) · BioCryst Pharmaceuticals (1) · Children's Hospital of Philadelphia (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Novartis Pharmaceuticals (1) · Sixera Pharma (1)
United States (6) · France (3) · Germany (2) · Netherlands (2) · Australia (1) · Austria (1) · Sweden (1) · United Kingdom (1)
Albert C Yan, MD (1) · Jemima Mellerio, Dr (1) · Maarten de Chateau, MD PhD (1) · Mary Spellman, MD (1)
2025 (1)